Italian Group for Adult Hematologic Diseases, Data Center and Health Outcomes Research Unit, Rome, Italy.
Blood. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12.
The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: -22.6 (P < .001), -22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.
本研究的主要目的是调查长期接受伊马替尼治疗的慢性髓性白血病（CML）患者的健康相关生活质量（HRQOL）是否与普通人群不同。共纳入 448 例 CML 患者，使用 SF-36 健康调查量表比较通用 HRQOL 概况。还评估了症状。对关键可能的混杂因素进行了 HRQOL 比较调整。患者的中位年龄为 57 岁，伊马替尼治疗的中位时间为 5 年（范围 3-9 年）。在年轻患者中发现了最大的 HRQOL 差异。特别是，18-39 岁的患者分别因身体和情绪问题导致角色限制出现明显障碍：分别为-22.6（P <.001）和-22.3（P <.001）。60 岁或以上的 CML 患者的 HRQOL 与普通人群报告的非常相似。与普通人群中的同龄人相比，女性的 HRQOL 比男性差。疲劳是最常报告的症状。CML 患者的 HRQOL 在许多方面与人群正常值相当，但年轻和女性患者似乎报告了主要的限制。
